Role of Candida antigen in treatment of viral warts: a placebo-controlled study
Keywords:
Candida antigen, viral warts, intradermal, intralesionalAbstract
Background Warts are a common skin disorder. They are caused by human papillomavirus (HPV). The currently available therapies are based on local destruction of the lesion. Other treatment options include immunotherapy. Candida antigen acts as an immune modulator. It causes resolution of warts in the vicinity of the injection and also at distant sites, when given intralesional and intradermal simultaneously. Objectives To determine the efficacy and safety of intradermal and intralesional Candida antigen in comparison with the placebo in the treatment of viral warts. Patients and methods It was an interventional (qausi experimental) study, carried out in out-patient, Department of Dermatology, Unit II, Mayo Hospital, Lahore. Patients were divided into two groups of 30 each. Group A was given 0.1 ml of Candida antigen and group B was given 0.1 ml of normal saline intradermally and intralesionally. Maximum of 1 ml was given per visit. Total of three doses were given each one month apart. Patients were followed up for three months after the last dose. Results The treatment was effective in about 67% of patients receiving Candida antigen therapy, whereas, in the control group only 20% patients showed improvement (p<0.05). The results were statistically significant. The antigen was well tolerated and the side effects produced were mainly local and only transient.ÂReferences
Fleisher AB Jr, Feldman SR, McConnell RC. The most common dermatologic problems identified by family physicians 1990-1994. Family Med 1997; 29: 648-52.
Yasmeen N, Khan M R, Spectrum of common childhood skin diseases: a single center experience. JPMA 2005; 2: 20-5.
Naheed T, Akbar N, Akbar N, Shehzad M. Skin manifestations amongst diabetic patients admitted in a general ward for various other medical problems. Pak J Med Sci 2002; 18: 291-6.
Yazar S, Basaran E. Efficacy of silver nitrate pencils in the treatment of warts. J Dermatol 1994; 21: 329-33.
Sloan K, Haberman H, Lynde CW. Carbon dioxide laser treatment for resistant verrucae vulgaris: retrospective analysis. J Cutan Med Surg 1997; 21: 500-5.
Sneff H, Reinel D, Matthies C et al. Topical 5-fluorouracil solution in the treatment of warts: clinical experience and percutaneous absorption. Br J Dermatol 1988; 118: 609-14.
Iwatsuki K, Tagami H, Takigawa M et al. Plane warts under spontaneous resolution. Arch Dermatol 1986; 122: 655-9.
Coleman N, Birley HDL, Renton A et al. Immunological events in regressing genital wart. Am J Clin Pathol 1994; 102: 768-74.
Ritter SE, Meffert J. Successful treatment of flat warts using intralesional candida antigen. Arch Dermatol 2003; 139: 541-2.
Phillips RC, Ruhl TS, Pfenninge JL, Garber MR. Treatment of warts with candida antigen injection. Arch Dermatol 2000; 136: 1274-5.
Johnson SM, Roberson PK, Horn TD. Intralesional injection of mumps or candida skin test antigen: a novel immunotherapy for warts. Arch Dermatol 2001; 137: 451-55.
Clifton MM, Johnson SM, Roberson PK et al. Immunotherapy for recalcitrant warts in children using intralesional mumps or candida antigens. Pediatr Dermatol 2003; 20: 268-71.
Horn TD, Johnson SM, Helm RM, Roberson PK. Intralesional immunotherapy of warts with mumps, candida and trichophyton skin test antigen. Arch Dermatol 2005; 141: 585-94.
Signore RJ. Candia albicans intralesional injection immunotherapy of warts. Cutis 2002; 70:155-6.
Sterling JC. Virus infections. In: Burns T, Breathnack S, Cox N, Griffiths C. Rook’s Textbook of Dermatology, 7th edn. Oxford: Blackwell Science; 2004. P.25.1-25.83.
